Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contributions to Cognitive Impairment and Dementia (VCID)(R01 - Clinical Trial Not Allowed) | PAR 24 196

FAQs: NIH PAR-24-196 (R01) - Diffuse White Matter Disease Mechanisms in VCID

1) What is this funding opportunity (PAR-24-196) about?

This NIH opportunity supports R01 research projects focused on understanding the mechanistic and hemodynamic drivers of diffuse white matter disease as it relates to vascular contributions to cognitive impairment and dementia (VCID). The goal is to explain how vascular and blood-flow problems connect to cellular and molecular injury in white matter and how those injuries affect brain function in ways that could plausibly contribute to cognitive symptoms.

2) What kinds of research does NIH want to fund under this FOA?

The FOA emphasizes basic and translational mechanistic research. Projects are expected to investigate why diffuse white matter disease develops, why some brain regions are more vulnerable, how the disease progresses over time, and what it does to axons and neural circuits. The program is motivated by the high prevalence of these lesions in older adults and their repeated association with cognitive decline and dementia in both men and women.

3) What is diffuse white matter disease, as described in the FOA?

Diffuse white matter disease is described as extremely common in older adults and repeatedly linked in clinical studies to later-life cognitive decline and dementia. On brain imaging it is often seen as white matter hyperintensities on MRI or as signal changes on CT. It can also be confirmed with histology in human tissue or in animal models.

4) Why is NIH prioritizing mechanistic work in this area?

Even though clinicians frequently encounter these lesions, the field still lacks a clear, detailed explanation of why they develop, why certain regions are vulnerable, how the disease progresses over time, and what the functional consequences are for axons and neural circuits. The FOA is intended to close these knowledge gaps with foundational mechanistic evidence.

5) Does this FOA support clinical trials?

No. Clinical trials are not allowed under this announcement.

6) Is this FOA about testing treatments in people?

No. The scientific focus is on basic and translational mechanisms rather than testing treatments in people. The long-term aim is foundational knowledge that can guide future prevention and intervention strategies, not immediate clinical testing.

7) What are the major scientific themes emphasized by the FOA?

A central theme is connecting vascular and blood flow related problems (for example, hemodynamics, perfusion deficits, and vessel disease) to downstream cellular and molecular injury mechanisms in white matter, and then linking those injuries to tissue-level and circuit-level dysfunction that could help explain cognitive symptoms.

8) What pathologies may contribute to diffuse white matter disease according to the FOA?

The FOA notes that diffuse white matter disease likely reflects a mixture of pathologies. Examples highlighted include demyelination and/or loss of white matter fibers driven by multifocal infarction and chronic local ischemia.

9) What vascular conditions are commonly associated with these lesions?

Diffuse white matter disease is commonly associated with arteriosclerosis of deep penetrating arteries. The FOA also notes that it may co-occur with small infarcts in structures such as the basal ganglia, brainstem, or cerebellum.

10) What brain regions are mentioned as relevant locations for diffuse white matter disease?

The FOA identifies periventricular white matter as a classic location, and also notes that subcortical white matter can be affected.

11) What biological scales should responsive projects address?

Projects responsive to this opportunity are expected to dig into biological mechanisms at multiple scales, including molecular pathways, cellular responses, tissue vulnerability patterns across brain regions, and consequences for neural signaling and network behavior.

12) What cell types or processes are specifically called out?

The FOA gives examples of relevant cellular responses and processes such as oligodendrocytes, myelin maintenance, axonal integrity, and interactions among glial and vascular cells.

13) What does the FOA say is still largely unknown?

The FOA emphasizes that the physiological impact of diffuse white matter disease on local axons and circuit function remains largely unknown. Studies that clarify how lesions disrupt communication in the brain and contribute to cognitive impairment are aligned with these stated gaps.

14) How does this FOA relate to VCID?

The research focus is framed around vascular contributions to cognitive impairment and dementia (VCID). The FOA is interested in mechanistic links from vascular dysfunction and perfusion problems to white matter injury and then to circuit-level dysfunction that could plausibly contribute to cognitive symptoms.

15) What is the long-term goal of the program?

The long-term aim is to build foundational knowledge that can guide future prevention and intervention strategies to reduce the public health burden of VCID, rather than immediate clinical testing.

16) What grant mechanism is used for this opportunity?

This is a discretionary NIH grant using the R01 mechanism.

17) What is the listed application due date?

The listed application due date is 2024-10-04.

18) Is there an award ceiling listed for this opportunity?

Yes. The opportunity includes an award ceiling of $500,000 (as provided in the source information).

19) Is this a new program, or does it build on earlier NIH solicitations?

This FOA is described as a reissue of prior NIH solicitations in this scientific area (RFA-NS-16-021, PAR-18-413, and RFA-NS-19-039), signaling continued NIH interest in strengthening mechanistic understanding of age-related cerebrovascular and white matter disease.

20) Who is eligible to apply?

Eligibility is broad and includes public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and many government entities (state, county, city/township, special districts), as well as independent school districts and public housing authorities/Indian housing authorities.

21) Are specific institution types explicitly encouraged or called out?

Yes. The eligibility description explicitly calls out several categories often emphasized for inclusive participation, including HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions. It also mentions faith-based or community-based organizations and certain tribal governments and regional organizations.

22) Are foreign (non-U.S.) organizations eligible to apply directly?

No. Foreign (non-U.S.) entities are not eligible to apply.

23) Are non-U.S. components of U.S. organizations eligible?

No. Non-U.S. components of U.S. organizations are not eligible under this announcement.

24) Can a U.S.-based applicant include any international elements in the project?

Yes, certain international elements may be included as foreign components as defined by NIH policy, if they are well-justified and meet NIH definitions and requirements. This is different from a foreign organization applying directly, which is not allowed.

25) What CFDA numbers are associated with this opportunity?

The CFDA numbers associated with this opportunity are 93.853 and 93.866.

26) What types of evidence or approaches are implied as relevant based on the description?

Based on the description, relevant approaches include imaging-based characterization (MRI white matter hyperintensities and CT signal changes), histology in human tissue, and animal models, in service of mechanistic studies that connect vascular/hemodynamic dysfunction to cellular injury and circuit-level outcomes.